Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy

ClinicalTrials.gov ID: NCT07220811

Public ClinicalTrials.gov record NCT07220811. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2b Randomized, Double-Blind, Placebo-Controlled Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy: This is a Phase 2b randomized, double-blind, placebo-controlled clinical trial evaluating RPT904, a next-generation anti-IgE monoclonal antibody, in people with food allergy. RPT904 is a long-acting antibody that may allow for dosing every 8 to 12 weeks. Approximately 100 participants between the ages of 12 and 55 with documented allergy to at least one of the following foods: peanut, milk, egg, cashew, or walnut will be enrolled. In Part 1 (24 weeks), participants will be randomly assigned to receive RPT904 every 8 or 12 weeks (plus a loading dose at Week 2), or placebo. In Part 2 (24 weeks), participants who received RPT904 will continue on their assigned dosing schedule, and those who previously received placebo will be re-randomized to receive RPT904 either every 8 or 12 weeks (plus a loading dose at Week 26). All participants will attend study visits approximately every 2-6 weeks throughout both Part 1 and Part 2 to maintain blinding, regardless of treatment group or dosing frequency. The study is being conducted at multiple sites. The primary goal is to assess whether RPT904 helps participants tolerate higher amounts of a food allergen without dose-limiting allergic symptoms during a food challenge. The study will also monitor the safety and side effects of RPT904 over time. Each participant is expected to be in the study for about 68 to 74 weeks, including screening, treatment, and follow-up.

Study identification

NCT ID: NCT07220811
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: RAPT Therapeutics, Inc.; Industry
Enrollment: 100 participants

Conditions and interventions

Conditions

Ig-E Mediated Food Allergy

Interventions

RPT904 Drug
Placebo Other

Drug · Other

Eligibility (public fields only)

Age range: 12 Years to 55 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 21, 2025
Primary completion: Mar 31, 2027
Completion: Dec 31, 2027
Last update posted: Jul 27, 2026

2025 – 2028

United States locations

U.S. sites: 22
U.S. states: 16
U.S. cities: 21

Facility	City	State	ZIP	Site status
Phoenix Childrens	Phoenix	Arizona	85016	Recruiting
Arkansas Children's	Little Rock	Arkansas	72202	Recruiting
Sean N. Parker Center for Allergy and Asthma Research	Palo Alto	California	94304	Recruiting
Children's Hospital Colorado	Aurora	Colorado	80045	Recruiting
Asthma & Allergy Associates, P.C.	Colorado Springs	Colorado	80907	Recruiting
National Jewish Health	Denver	Colorado	80206	Recruiting
Children's National Hospital	Washington D.C.	District of Columbia	20010	Recruiting
University of South Florida	Tampa	Florida	33613	Recruiting
Children's Healthcare of Atlanta - Center for Advanced Pediatrics	Atlanta	Georgia	30329	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Boston's Children's Hospital	Boston	Massachusetts	02115	Recruiting
University of Michigan	Ann Arbor	Michigan	48109	Recruiting
Clinical Research Institute, Inc	Minneapolis	Minnesota	55402	Recruiting
Northwell Health	Great Neck	New York	11021	Recruiting
Icahn School of Medicine at Mount Sinai	New York	New York	10029	Recruiting
University of North Carolina at Chapel Hill Clinical and Translational Research Center( CTRC)	Chapel Hill	North Carolina	27599	Recruiting
Cincinnati Children's Hospital	Cincinnati	Ohio	45229	Recruiting
The Children's Hospital of Philadelphia	Philadelphia	Pennsylvania	19104	Recruiting
UPMC Children's Hospital of Pittsburgh	Pittsburgh	Pennsylvania	15224	Recruiting
Vanderbilt University	Nashville	Tennessee	37232	Recruiting
Dell Children's Medical Group	Austin	Texas	78723	Recruiting
Texas Children's Hospital	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07220811, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 27, 2026 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07220811 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →